methanesulfonic acid 2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethyl ester | 494850-87-2

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: methanesulfonic acid 2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethyl ester
• 英文别名: 2-[2-Methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethyl methanesulfonate；2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethyl methanesulfonate
• CAS: 494850-87-2
• 化学式: C₁₅H₁₉NO₃S₂
• 分子量: 325.453
• InChiKey: ZEHQRPDYFZUDKB-UHFFFAOYSA-N

物化性质

• 沸点：
  511.3±50.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  82
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methanesulfonic acid 2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethyl ester 在 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 乙醇 、 环己烷 为溶剂， 反应 44.0h， 生成 (S)-(-)α-1-phenylethylamine salt of (S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio) phenyl]-1H-pyrrol-1-yl]ethoxy]benzene-propanoic acid
  参考文献：
  名称：

  [EN] POLYMORPHIC FORM OF PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF
  [FR] FORME POLYMORPHE DE DÉRIVÉ DU PYRROLE ET INTERMÉDIAIRE

  摘要：

  本发明涉及公式（IA）的Saroglitazar游离酸或其药学上可接受的盐、药学上可接受的溶剂化物、药学上可接受的酯、立体异构体、互变异构体、类似物和其衍生物。本发明还提供了Saroglitazar游离酸的非晶态形式及其制备方法。本发明还提供了包含非晶态Saroglitazar镁的制药组合物。

  公开号：

  WO2015029066A1
• 作为产物：
  描述：

  2-[2-(4-methylsulfanylphenyl)-2-oxoethyl]-3-oxobutanic acid methyl ester 在 水 、 三乙胺 、 sodium hydroxide 、 三甲基乙酸 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 1.0h， 生成 methanesulfonic acid 2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethyl ester
  参考文献：
  名称：

  [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES
  [FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE DÉRIVÉS DE PYRROLE

  摘要：

  公开号：

  WO2015033357A3

文献信息

• COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20220023262A1

  公开（公告）日：2022-01-27

  The present invention relates to a composition comprising high purity pyrrole derivative and method for preparation thereof. The present invention particularly relates to compositions comprising Saroglitazar magnesium having purity of 99.0% or more, and one or more of an aldehyde compound of Formula (II), diketo oxirane compound of Formula (III), hydroxy methyl compound of Formula (IV) or dimer compound of Formula (V), relative to saroglitazar magnesium, each present in an amount of about 0.15% or less, respectively, by weight, when measured by area percentage of HPLC.

  本发明涉及一种包含高纯度吡咯衍生物的组合物及其制备方法。本发明特别涉及含有纯度达到99.0%或更高的沙罗格利他酸镁的组合物，以及相对于沙罗格利他酸镁，分别以大约0.15%或更少的重量含量存在的醛类化合物（式（II））、二酮氧环烷化合物（式（III））、羟甲基化合物（式（IV））或二聚体化合物（式（V）），通过HPLC面积百分比测量。
• PYRROLE COMPOUND, COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF
  申请人：Cadila Healthcare Ltd.

  公开号：US20180265466A1

  公开（公告）日：2018-09-20

  The present invention relates to compositions comprising saroglitazar magnesium wherein the saroglitazar magnesium has a purity of greater than or equal to 99% by weight, and dimer compound of Formula (IV) present in an amount relative to saroglitazar magnesium less than about 0.3% by weight by area percentage of HPLC. The present invention also related to the process for the preparation thereof and pharmaceutical compositions comprising the same.

  本发明涉及含有萨罗格利他酸镁的组合物，其中萨罗格利他酸镁的纯度大于或等于99％重量，并且在HPLC的面积百分比下，相对于萨罗格利他酸镁的二聚体化合物的含量小于约0.3％重量。本发明还涉及其制备方法和含有该组合物的制药组合物。
• TREATMENT FOR LIPODYSTROPHY
  申请人：Gambhire Dhiraj

  公开号：US20130338209A1

  公开（公告）日：2013-12-19

  The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

  本发明提供了一种治疗化合物(I)及其在预防和治疗因HIV感染或HIV-1蛋白酶抑制剂（Pis）和/或逆转录酶抑制剂（nRTIs）联合治疗引起的脂肪萎缩症的药物可接受盐，通过中和HIV患者的脂肪肥大、脂肪萎缩和代谢异常。
• [EN] NOVEL PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE<br/>[FR] NOUVEAUX PYRROLES POSSEDANT DES ACTIVITES HYPOLIPIDEMIANTES ET HYPOCHOLESTEROLEMIANTES, PROCEDE DE PREPARATION DE CEUX-CI, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION EN MEDECINE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2003009841A1

  公开（公告）日：2003-02-06

  The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine. The compounds lower triglyceride levels in blood and may be useful in the treatment of obesity, hyperlipidaemia, hypercholesteremia, syndrome X and diabetes.

  本发明涉及一种新型取代吡咯化合物、其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明特别涉及一般式（I）的新型取代吡咯化合物、其类似物、衍生物、多晶形态、互变异构体、药学上可接受的盐、药学上可接受的溶剂和含有它们的药物组合物。本发明还涉及制备这种化合物的过程、含有这种化合物的组合物以及在医学上使用这种化合物和组合物的用途。这些化合物可以降低血液中的甘油三酯水平，可能有助于治疗肥胖症、高脂血症、高胆固醇血症、X综合症和糖尿病。
• Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
  申请人：——

  公开号：US20030236254A1

  公开（公告）日：2003-12-25

  Novel &bgr;-aryl-&agr;-substituted propanoic acids having hypolipidemic and hypocholesteremic activities.

  具有降脂和降胆固醇活性的新型&bgr;-芳基-&agr;-取代丙酸。